Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor
暂无分享,去创建一个
[1] Ying Wang,et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis , 2005, Oncogene.
[2] R. Motzer,et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .
[3] G. Demetri,et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST , 2005 .
[4] S. Ropero,et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[6] Jeffrey W. Smith,et al. Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.
[7] P. Febbo,et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.
[8] D. Mukhopadhyay,et al. Heterotrimeric Gαq/Gα11 Proteins Function Upstream of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (KDR) Phosphorylation in Vascular Permeability Factor/VEGF Signaling* , 2003, Journal of Biological Chemistry.
[9] K. David,et al. Key role of mitochondria in cerulenin-mediated apoptosis , 2002, Cell Death and Differentiation.
[10] T. Roskams,et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.
[11] J. Burbaum,et al. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site‐directed probes , 2001, Proteomics.
[12] A. Joshi,et al. Mapping the functional topology of the animal fatty acid synthase by mutant complementation in vitro. , 2001, Biochemistry.
[13] D. Chan,et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. , 2001, Cancer letters.
[14] Ziwei Gu,et al. Human fatty acid synthase: Role of interdomain in the formation of catalytically active synthase dimer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Gorospe,et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.
[16] B. Cravatt,et al. Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[17] S. Takenoshita,et al. Fatty acid synthase expression in Japanese breast carcinoma patients. , 1999, International journal of molecular medicine.
[18] Joseph A. DiGiuseppe,et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. , 1998, Cancer research.
[19] D. Hicklin,et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.
[20] Y. Furuya,et al. Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. , 1997, Anticancer research.
[21] W. Bornmann,et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] T. Gansler,et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. , 1997, Human Pathology.
[23] A. Witkowski,et al. Mapping of functional interactions between domains of the animal fatty acid synthase by mutant complementation in vitro. , 1997, Biochemistry.
[24] D. Maguire,et al. A novel in vitro assay for human angiogenesis. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[25] C. Jackisch,et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. , 1996, Cancer research.
[26] G. Pasternack,et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.
[27] P. Visca,et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.
[28] J. Martial,et al. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] L. Jacobs,et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Wakil,et al. The architecture of the animal fatty acid synthetase complex. IV. Mapping of active centers and model for the mechanism of action. , 1983, The Journal of biological chemistry.
[31] S. Wakil,et al. The architecture of the animal fatty acid synthetase. II. Separation of the core and thioesterase functions and determination of the N-C orientation of the subunit. , 1983, The Journal of biological chemistry.
[32] J. Menéndez,et al. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. , 2005, Medical hypotheses.
[33] D. Mukhopadhyay,et al. Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. , 2003, The Journal of biological chemistry.
[34] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] C. Townsend,et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Winer,et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. , 1992, Growth factors.